Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biologic response modifiers in primary immunodeficiency disorders.

A Hassner1, D C Adelman

  • 1Tel Aviv Elias-Sourasky Medical Center, Israel.

Annals of Internal Medicine
|August 15, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outdoor attractancy of males ofMatsucoccus josephi (Homoptera: Matsucoccidae) andElatophilus hebraicus (Hemiptera: Anthocoridae) to synthetic female sex pheromone ofMatsucoccus josephi.

Journal of chemical ecology·2013
Same author

Peptide conjugation: unexpected ring opening of azacrown ether nucleophiles in the oxazolone-based coupling.

Chemical communications (Cambridge, England)·2002
Same author

Conformational preferences for 3-piperideines: an Ab initio and molecular mechanics study.

Chemistry (Weinheim an der Bergstrasse, Germany)·2002
Same author

Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer.

Human pathology·2001
Same author

Synthesis and anticancer activity of novel chiral D-glucose derived bis-imidazoles and their analogs.

Carbohydrate research·2001
Same author

Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells.

Arteriosclerosis, thrombosis, and vascular biology·2001
Same journal

Correction to I.M. Matters News: Sleep medicine for seniors.

Annals of internal medicine·2026
Same journal

Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

Annals of internal medicine·2026
Same journal

Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

Annals of internal medicine·2026
Same journal

Grappling with GLP-1 prescribing.

Annals of internal medicine·2026
See all related articles

A new classification for primary immunodeficiency disorders (PIDs) based on functional defects is proposed. Biologic response modifiers offer promising therapeutic avenues for PIDs, with further research essential for optimizing their use.

Area of Science:

  • Immunology
  • Genetics
  • Pharmacology

Background:

  • Primary immunodeficiency disorders (PIDs) encompass a heterogeneous group of genetic conditions affecting the immune system.
  • Understanding the functional basis of PIDs is crucial for developing targeted therapies.

Purpose of the Study:

  • To introduce a novel classification system for PIDs based on functional abnormalities.
  • To explore the therapeutic potential of biologic response modifiers (BRMs) in managing PIDs.

Main Methods:

  • A comprehensive literature search was conducted using MEDLINE, focusing on PIDs and human immunomodulators.
  • Relevant articles were critically reviewed for inclusion.

Main Results:

  • PIDs are classified by functional defects: cellular maturation, differentiation, regulatory cell function, enzymatic function, and cytokine responses.

Related Experiment Videos

  • BRMs like intravenous immunoglobulin, H2-receptor blockers, retinoids, gene therapy, enzyme replacement, and interferons show potential for specific PID types.
  • Interleukin-2, thymic hormones, transfer factor, and levamisole may address multiple functional defects.

    • Conclusions:

    • BRMs are valuable adjunctive therapies for PIDs, with increasing future importance.
    • Multi-center trials are necessary to establish the definitive roles and efficacy of BRMs in PID treatment.